According to a new study published online in The New England Journal of Medicine, a humanized IgG4 monoclonal antibody that binds to CD4 extracellular domain 2 reduced viral load in patients with multidrug-resistant HIV-1.

According to a new study published in the New England Journal of Medicine, patients with HIV covered by Medicaid who had medical comorbidities and behavioral health disorders had fewer inpatient services, more outpatient services, and overall lower costs when treated in a patient-centered medical home.

A humanized immunoglobulin G4 monoclonal antibody improved antiviral activity among patients with multidrug-resistant HIV-1, according to a new study published in The New England Journal of Medicine. 

Comorbidities like hepatitis C virus, renal, liver, and chronic pulmonary diseases significantly boosted the risk of hospitalization and costs of patients with HIV, a recent study suggests.

The International Antiviral Society–USA Panel has released a set of updated recommendations for the treatment of patients with HIV, including universal screening for anyone who has been sexually active and rapid start for all eligible newly diagnosed patients.

According to a new study in The American Journal of Managed Care, less restrictive formulary designs, which allow patients with HIV to initiate potentially safer and more efficacious regimens, result in better outcomes and cost reductions. 

Two recent trials published in The Lancet HIV found that adults with HIV who switched from dolutegravir-abacavir-lamivudine or from boosted protease inhibitor-based regimens to a fixed-dose of Biktarvy (bictegravir-emtricitabine-tenofovir; Gilead) maintained virologic suppression.

Public health officials are expanding efforts to get the HIV prevention pill into the hands of those at risk, in a nationwide effort to curb infections, however, the costs of these treatments are becoming more of a burden for patients.

According to a recent study, nonadherence among Medicaid insured patients with HIV led to an increase in health care resource utilization and overall costs.

Recent research examined a new simulation modeling framework to predict how effective certain pre- and post-exposure prophylaxis drugs will work to prevent HIV infection.